bioRxiv Science⌕ Search

Biology subjects

Kwon, N.

Publications and source records attributed to Kwon, N..

5 recordsLinked to original sources

Click alginate cryogel for real-time gastric pH monitoring

Gastric acidity shapes mucosal injury in reflux disease, peptic ulcer, and gastritis, yet is almost never measured. Acid-suppressive therapy, taken by approximately 40% of elderly adults, is therefore titrated on symptoms alone. A gastric sensor must hold onto its reporter in a highly acidic protease-rich environment, conditions that destabilize ionically crosslinked hydrogels and leach physically entrapped dyes. Click alginates, established in biomechanics and drug delivery but not as sensors, meet this requirement with a single chemistry: bioorthogonal tetrazine-norbornene crosslinks are inert to acid and proteases, and excess norbornene from crosslinking become the anchoring site for the pH-sensitive reporter, so network and reporter are installed by the same mechanism. Cryogelation adds macroporosity for rapid gastric fluid influx. A screen identifies IRDye 680RD as the only near-infrared dye responsive across the targeted pH 2-5. Dye release stays below 1.5% in simulated gastric and intestinal fluids, and the pH response remains active after nine months of storage. In rats, the orally administered NIR fluorescent cryogel resolves pH 2.0 from pH 5.0 transabdominally, and discriminates esomeprazole- from saline-treated animals, without plasma fluorescence. Photoacoustic imaging points toward detection at translationally relevant depths, establishing covalently functionalized cryogels as a general sensing platform for hostile physiological environments.

bioengineering↗

Portable transcranial therapeutic ultrasound enhances targeted gene delivery for Parkinson's disease: from rodent models to non-human primates

Gene therapy for neurodegenerative diseases faces significant challenges due to the blood-brain barrier (BBB), which limits drug delivery to the central nervous system (CNS). While clinical trials for Parkinsons disease (PD) have progressed, administration of vectors expressing enzymatic or neurotrophic factor transgenes have required extensive optimization of the delivery method to achieve potentially therapeutic levels of transgene expression. Focused ultrasound (FUS) combined with microbubbles has emerged as a promising non-invasive strategy to transiently open the BBB for targeted gene delivery via viral nanocarriers including recombinant adeno-associated viruses (AAVs). However, key factors influencing FUS-mediated AAV delivery, including dose distribution and therapeutic efficacy, remain underexplored in non-human primates (NHPs). Here, we evaluated the feasibility of AAV9-CAG-GFP delivery using two portable therapeutic ultrasound modalities: ultrasound-guided, spherically-focused FUS (USgFUS) and a novel low-frequency linear array configuration for imaging and therapy called theranostic ultrasound (ThUS). In mice, FUS-sonicated regions exhibited a 25-fold increase in AAV9 biodistribution compared to systemic injection alone. Extending this approach to NHPs, we observed up to a 200-fold increase in AAV9 DNA in treated brain regions, including PD-relevant structures. In assessing the translational therapeutic potential of this technique, ThUS-mediated AAV9-hSyn-hNTRN (human neurturin) delivery in a toxin mouse model of PD facilitated the rescue of up to 80% and 75% of degenerated dopaminergic neurons in the substantia nigra and striatum, respectively. These findings demonstrate that portable ultrasound technologies can non-invasively enhance AAV9 delivery to targeted brain regions in both mice and NHPs relative to what can be achieved with intravenous (IV) delivery of the same capsid alone. With further development, these approaches may offer a clinically viable, non-invasive alternative for gene therapy in neurodegenerative diseases. One sentence summaryBBB opening with portable therapeutic ultrasound non-invasively increased viral gene delivery to the brain after systemic AAV vector administration in mice and rhesus macaques.

bioengineering↗

Focused ultrasound enhanced antibody delivery for the treatment of Parkinson's Disease

Treatment of neurological disorders is partly impeded by the size of large pharmacological agents which are thereby unable to bypass the blood-brain barrier (BBB). Focused ultrasound (FUS) in conjunction with systemically administered microbubbles has been shown to safely, non-invasively and transiently open the BBB, allowing the passage of large biomolecules to the brain parenchyma through the otherwise impermeable barrier. This pilot study assessed the feasibility of FUS-mediated delivery of an anti-alpha-synuclein (-syn) monoclonal antibody (mAb) in Parkinsons disease (PD) mouse models that exhibit -syn aggregates. Mice (n=21) underwent FUS on a weekly basis over the course of 2-3 weeks, followed by a one-month survival period. MRI and microscopy were performed to confirm BBB opening with FUS and visualize antibody delivery. Safety was assessed in vivo using passive cavitation detection and immunohistochemistry to evaluate microglial and astrocyte activity ex vivo. It was found that treatment sessions for multiple FUS sessions of targeted antibody delivery was feasible in alpha-synuclein models facilitating immunotherapeutics for PD.

neuroscience↗

Functional ultrasound (fUS) imaging of displacement-guided focused ultrasound (FUS) neuromodulation in mice

Focused ultrasound (FUS) stimulation is a promising neuromodulation technique with the merits of non-invasiveness, high spatial resolution, and deep penetration depth. However, simultaneous imaging of FUS-induced brain tissue displacement and the subsequent effect of FUS stimulation on brain hemodynamics has proven challenging thus far. In addition, earlier studies lack in situ confirmation of targeting except for the magnetic resonance imaging-guided FUS system-based studies. The purpose of this study is 1) to introduce a fully ultrasonic approach to in situ target, modulate neuronal activity, and monitor the resultant neuromodulation effect by respectively leveraging displacement imaging, FUS, and functional ultrasound (fUS) imaging, and 2) to investigate FUS-evoked cerebral blood volume (CBV) response and the relationship between CBV and displacement. We performed displacement imaging on craniotomized mice to confirm the in targeting for neuromodulation site. We recorded hemodynamic responses evoked by FUS and fUS revealed an ipsilateral CBV increase that peaks at 4 s post-FUS. We saw a stronger hemodynamic activation in the subcortical region than cortical, showing good agreement with the brain elasticity map that can also be obtained using a similar methodology. We observed dose-dependent CBV response with peak CBV, activated area, and correlation coefficient increasing with ultrasonic dose. Furthermore, by mapping displacement and hemodynamic activation, we found that displacement colocalizes and linearly correlates with CBV increase. The findings presented herein demonstrated that FUS evokes ipsilateral hemodynamic activation in cortical and subcortical depths and the evoked hemodynamic responses colocalized and correlate with FUS-induced displacement. We anticipate that our findings will help consolidate accurate targeting as well as an understanding of how FUS displaces brain tissue and affects cerebral hemodynamics.

bioengineering↗

Focused ultrasound-mediated brain genome editing

Gene editing in the mammalian brain has been challenging because of the restricted transport imposed by the blood-brain barrier (BBB). Current approaches rely on local injection to bypass the BBB. However, such administration is highly invasive and not amenable to treating certain delicate regions of the brain. We demonstrate a safe and effective gene editing technique by using focused ultrasound (FUS) to transiently open the BBB for the transport of intravenously delivered CRISPR/Cas9 machinery to the brain.

bioengineering↗